Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity-Reference-Cited by-同舟云学术

Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity

Published:2021-11-17 Issue:620 Volume:13 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Prinzing Brooke¹^ORCID,Zebley Caitlin C.¹²³⁴^ORCID,Petersen Christopher T.¹,Fan Yiping⁵^ORCID,Anido Alejandro Allo¹^ORCID,Yi Zhongzhen¹^ORCID,Nguyen Phuong¹,Houke Haley¹^ORCID,Bell Matthew¹⁴,Haydar Dalia¹^ORCID,Brown Charmaine²^ORCID,Boi Shannon K.²^ORCID,Alli Shanta²^ORCID,Crawford Jeremy Chase²^ORCID,Riberdy Janice M.¹,Park Jeoungeun J.¹^ORCID,Zhou Sheng¹^ORCID,Velasquez Mireya Paulina¹^ORCID,DeRenzo Chris¹^ORCID,Lazzarotto Cicera R.⁶^ORCID,Tsai Shengdar Q.⁶,Vogel Peter⁷^ORCID,Pruett-Miller Shondra M.⁸^ORCID,Langfitt Deanna M.¹^ORCID,Gottschalk Stephen¹^ORCID,Youngblood Ben²^ORCID,Krenciute Giedre¹^ORCID

Affiliation:

1. Department of Bone Marrow Transplantation and Cellular Therapy, St Jude Children’s Research Hospital, Memphis, TN 38105, USA.

2. Department of Immunology, St Jude Children’s Research Hospital, Memphis, TN 38105, USA.

3. Department of Oncology, St Jude Children’s Research Hospital, Memphis, TN 38105, USA.

4. Graduate School of Biomedical Sciences, St Jude Children’s Research Hospital, Memphis, TN 38105, USA.

5. Department of Bioinformatics, St Jude Children’s Research Hospital, Memphis, TN 38105, USA.

6. Department of Hematology, St Jude Children’s Research Hospital, Memphis, TN 38105, USA.

7. Department of Pathology, St Jude Children’s Research Hospital, Memphis, TN 38105, USA.

8. Department of Cell and Molecular Biology, St Jude Children’s Research Hospital, Memphis, TN 38105, USA.

Abstract

DNMT3A deletion preserves CAR T cell functionality during prolonged stimulation.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference83 articles.

1. CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date

2. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

3. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

4. Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma

5. Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial

Cited by 166 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Decitabine consolidation after CD19/CD22 CAR-T therapy as a novel maintenance treatment significantly improves survival outcomes in relapsed/refractory B-ALL patients;Leukemia Research;2024-10

2. Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy;New England Journal of Medicine;2024-09-05

3. ReCARving the future: bridging CAR T-cell therapy gaps with synthetic biology, engineering, and economic insights;Frontiers in Immunology;2024-09-05

4. T cell exhaustion and senescence for ovarian cancer immunotherapy;Seminars in Cancer Biology;2024-09

5. mRNA-based therapeutic strategies for cancer treatment;Molecular Therapy;2024-09